Atrophy / karščiavimas

Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

Preparation and use of ortho-sulfonamide heteroarly hydroxamic acids as matrix metalloproteinase and TACE inhibitors

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metaloproteinase and tace inhibitors

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

Preparation and use of .beta.-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

TECHNICAL FIELD The present invention is directed to certain isoxazolone compounds that inhibit the release of inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor (TNF) from cells. The compounds of the invention, therefore, are useful in treating diseases involving unwanted

Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

TECHNICAL FIELD The present invention is directed to certain isoxazolone compounds that inhibit the release of inflammatory cytokines such as interleukin-1 (1L-1) and tumor necrosis factor (TNF) from cells. The compounds of the invention, therefore, are useful in treating diseases involving unwanted

Composition for treating arthritic disorder

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

TECHNICAL FIELD The present invention relates to compositions and methods for treating a joint disease, including veterinary applications. BACKGROUND For example, articular cartilage is hyaline cartridge that is composed of a small number of cells, collagenous extracellular matrix, abundant

Ubiquitin conjugating enzymes 7, 8 and 9

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are Ubiquitin

Ubiquitin conjugating enzymes 8 and 9

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are Ubiquitin

Ubiquitin conjugating enzymes 7,8 and 9

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

This application is entitled to the benefits of 35 U.S.C. .sctn.120 for priority based on PCT/US95/01250, filed 31 Jan. 1995. This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the

Ubiquitin conjugating enzymes 8 and 9

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

This application is entitled to the benefits of 35 USC .sctn.120 for priority based on PCT/US95/01250, filed 31 Jan. 1995. This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the

Pyrimidine compounds and their uses

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

FIELD Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. ##STR00002## The present invention also

Pyrimidine compounds and their uses

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

FIELD Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. ##STR00002## The present invention also

atrophy/karščiavimas

Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Preparation and use of ortho-sulfonamide heteroarly hydroxamic acids as matrix metalloproteinase and TACE inhibitors

Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metaloproteinase and tace inhibitors

Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Preparation and use of .beta.-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors

Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity

Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity

Composition for treating arthritic disorder

Ubiquitin conjugating enzymes 7, 8 and 9

Ubiquitin conjugating enzymes 8 and 9

Ubiquitin conjugating enzymes 7,8 and 9

Ubiquitin conjugating enzymes 8 and 9

Pyrimidine compounds and their uses

Pyrimidine compounds and their uses

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu